JP2025508359A - 化膿性汗腺炎を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド - Google Patents

化膿性汗腺炎を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド Download PDF

Info

Publication number
JP2025508359A
JP2025508359A JP2024546431A JP2024546431A JP2025508359A JP 2025508359 A JP2025508359 A JP 2025508359A JP 2024546431 A JP2024546431 A JP 2024546431A JP 2024546431 A JP2024546431 A JP 2024546431A JP 2025508359 A JP2025508359 A JP 2025508359A
Authority
JP
Japan
Prior art keywords
subject
administration period
months
biological sample
oxazepane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508359A5 (https=
Inventor
テパー，アリエル
マース，アンドレア
ヴェルガラ，マルセラ
ラミレス，クリスティーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insmed Inc
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of JP2025508359A publication Critical patent/JP2025508359A/ja
Publication of JP2025508359A5 publication Critical patent/JP2025508359A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024546431A 2022-02-16 2023-02-16 化膿性汗腺炎を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド Pending JP2025508359A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263310751P 2022-02-16 2022-02-16
US63/310,751 2022-02-16
PCT/US2023/062731 WO2023159120A1 (en) 2022-02-16 2023-02-16 Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Publications (2)

Publication Number Publication Date
JP2025508359A true JP2025508359A (ja) 2025-03-26
JP2025508359A5 JP2025508359A5 (https=) 2026-02-19

Family

ID=87579133

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546431A Pending JP2025508359A (ja) 2022-02-16 2023-02-16 化膿性汗腺炎を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド

Country Status (11)

Country Link
US (1) US20250144116A1 (https=)
EP (1) EP4479059A4 (https=)
JP (1) JP2025508359A (https=)
KR (1) KR20240148350A (https=)
CN (1) CN118695864A (https=)
AU (1) AU2023221393A1 (https=)
CA (1) CA3244131A1 (https=)
GB (1) GB2630719A (https=)
IL (1) IL314769A (https=)
MX (1) MX2024009995A (https=)
WO (1) WO2023159120A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (https=) 2014-01-24 2018-02-24
HUE070049T2 (hu) 2018-03-01 2025-05-28 Astrazeneca Ab (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil} -1,4-oxazepán-2-karboxamidot tartalmazó gyógyászati készítmények
WO2020018547A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (https=) * 2014-01-24 2018-02-24
KR20240091302A (ko) * 2016-07-29 2024-06-21 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
MX2021012548A (es) * 2019-04-17 2023-01-05 Azora Therapeutics Inc Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel.
WO2024026433A2 (en) * 2022-07-28 2024-02-01 Insmed Incorporated Novel dpp1 inhibitors and uses thereof

Also Published As

Publication number Publication date
US20250144116A1 (en) 2025-05-08
CN118695864A (zh) 2024-09-24
WO2023159120A1 (en) 2023-08-24
IL314769A (en) 2024-10-01
KR20240148350A (ko) 2024-10-11
MX2024009995A (es) 2024-08-22
CA3244131A1 (en) 2023-08-24
EP4479059A4 (en) 2026-01-28
AU2023221393A1 (en) 2024-08-15
EP4479059A1 (en) 2024-12-25
GB2630719A (en) 2024-12-04
GB202412566D0 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
US20250144116A1 (en) Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
US20220152056A1 (en) Methods and compositions for treating various disorders
JP2024540142A (ja) 慢性副鼻腔炎を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド
CA3113462A1 (en) Formulations of reproxalap for the treatment of dry eye disease
US11998553B2 (en) Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
TW202602439A (zh) 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
CN117503775A (zh) 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
JP2024511141A (ja) オリスミラストによる化膿性汗腺炎の治療
US20240366566A1 (en) Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
JP7696006B2 (ja) 化膿性汗腺炎の治療における使用のためのレミブルチニブ
US20260069578A1 (en) Treatment of neutrophilic dermatoses
JP2020530472A (ja) シュニッツラー症候群の治療方法
BRPI0713647A2 (pt) formulações farmacêuticas e composições de um antagonista seletivo cxcr2 ou cxcr1 e métodos para o uso do mesmo visando o tratamento de distúrbios inflamatórios
JPWO2005063253A1 (ja) アレルギー症状治療用医薬組成物
CN121796375A (zh) 用于预防和治疗糖尿病心肌病的化合物及其应用
WO2026067357A1 (zh) 托吡司特药物组合物、制备方法及应用
TW202126306A (zh) 嗜酸性球性病症之治療
HK40003409A (en) Treatment of prurigo nodularis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260210